Biotech Values

[ghmm]

I find the Q1 11 timetable aggressive since I would expect the trial to be ritonavir boosted. I believe Roche (or perhaps it was InterMune) said further INFORM trials would be longer in duration so I figured Roche would want a bit more data before initiation. I haven't kept up with things to know exactly where 191 was at but I certainly hope it gets started before Teva gets a generic Lovenox approval [which of course I hope doesn't occur].